- Home
- OKYO vs NVNO Comparison
OKYO vs NVNO Comparison
Compare OKYO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- NVNO
- Stock Information
- Founded
- OKYO 2007
- NVNO 1987
- Country
- OKYO United Kingdom
- NVNO United States
- Employees
- OKYO N/A
- NVNO N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- NVNO Medical/Dental Instruments
- Sector
- OKYO Health Care
- NVNO Health Care
- Exchange
- OKYO Nasdaq
- NVNO Nasdaq
- Market Cap
- OKYO 37.0M
- NVNO 41.0M
- IPO Year
- OKYO 2022
- NVNO N/A
- Fundamental
- Price
- OKYO $1.85
- NVNO $3.61
- Analyst Decision
- OKYO Strong Buy
- NVNO
- Analyst Count
- OKYO 1
- NVNO 0
- Target Price
- OKYO $7.00
- NVNO N/A
- AVG Volume (30 Days)
- OKYO 198.3K
- NVNO 88.4K
- Earning Date
- OKYO 06-06-2025
- NVNO 05-01-2025
- Dividend Yield
- OKYO N/A
- NVNO N/A
- EPS Growth
- OKYO N/A
- NVNO N/A
- EPS
- OKYO N/A
- NVNO N/A
- Revenue
- OKYO N/A
- NVNO N/A
- Revenue This Year
- OKYO N/A
- NVNO N/A
- Revenue Next Year
- OKYO N/A
- NVNO $409.09
- P/E Ratio
- OKYO N/A
- NVNO N/A
- Revenue Growth
- OKYO N/A
- NVNO N/A
- 52 Week Low
- OKYO $0.81
- NVNO $2.03
- 52 Week High
- OKYO $1.98
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- OKYO 62.66
- NVNO 55.25
- Support Level
- OKYO $1.70
- NVNO $3.26
- Resistance Level
- OKYO $1.98
- NVNO $3.81
- Average True Range (ATR)
- OKYO 0.18
- NVNO 0.25
- MACD
- OKYO 0.03
- NVNO -0.03
- Stochastic Oscillator
- OKYO 80.30
- NVNO 47.30
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.